Drug Sponsors Mostly 'On Track' With Postmarket Study Requirements
Executive Summary
US FDA's annual report on the status of postmarketing requirements and commitments shows 84% of open postmarket requirements for NDAs and 91% for BLAs were progressing on schedule as of Sept. 30, 2016; about half have not yet begun.
You may also be interested in...
Drug Sponsors Are On Schedule With Most Post-Approval Studies
US FDA's Gottlieb touts use of real world evidence as report shows vast majority of postmarketing requirements and commitments progressing on schedule.
Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing
Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.
Patient Data In Drug Reviews Would Be Encouraged In Proposed Amendment To User Fee Bill
Rep. Matsui withdrew amendment on FDA’s use of patient experience data during health subcommittee markup of user fee reauthorization legislation, but it may be considered in full committee markup following agency input. Chair Eshoo says the provision specifying contrast agents must be regulated as drugs needs to be reworked to include ophthalmic products.